Background: Sphingosine‐1‐phosphate plays vital roles in cardiomyocyte physiology, myocardial ischemia–reperfusion injury, and ischemic preconditioning. The function of the cardiomyocyte sphingosine‐1‐phosphate receptor 1 (S1P 1 ) in vivo is unknown. Methods and Results: Cardiomyocyte‐restricted deletion of S1P 1 in mice (S1P 1αMHCCre ) resulted in progressive cardiomyopathy, compromised response to dobutamine, and premature death. Isolated cardiomyocytes from S1P 1αMHCCre mice revealed reduced diastolic and systolic Ca 2+ concentrations that were secondary to reduced intracellular Na + and caused by suppressed activity of the sarcolemmal Na + /H + exchanger NHE ‐1 in the absence of S1P 1 . This scenario was successfully reproduced in wild‐type cardiomyocytes by pharmacological inhibition of S1P 1 or sphingosine kinases. Furthermore, Sarcomere shortening of S1P 1αMHCCre cardiomyocytes was intact, but sarcomere relaxation was attenuated and Ca 2+ sensitivity increased, respectively. This went along with reduced phosphorylation of regulatory myofilament proteins such as myosin light chain 2, myosin‐binding protein C, and troponin I. In addition, S1P 1 mediated the inhibitory effect of exogenous sphingosine‐1‐phosphate on β‐adrenergic–induced cardiomyocyte contractility by inhibiting the adenylate cyclase. Furthermore, ischemic precondtioning was abolished in S1P 1αMHCCre mice and was accompanied by defective Akt activation during preconditioning. Conclusions: Tonic S1P 1 signaling by endogenous sphingosine‐1‐phosphate contributes to intracellular Ca 2+ homeostasis by maintaining basal NHE ‐1 activity and controls simultaneously myofibril Ca 2+ sensitivity through its inhibitory effect on adenylate cyclase. Cardioprotection by ischemic precondtioning depends on intact S1P 1 signaling. These key findings on S1P 1 functions in cardiac physiology may offer novel therapeutic approaches to cardiac diseases.
1 October 2015 in Circulation: Arrhythmia and Electrophysiology
Background—: The Na + /Ca 2+ exchanger (NCX) has been implied to cause arrhythmias. To date, information on the role of NCX in arrhythmogenesis derived from models with increased NCX expression, hypertrophy, and heart failure. Furthermore, the exact mechanism by which NCX exerts its potentially proarrhythmic effect, ie, by promoting early afterdepolarization (EAD) or delayed afterdepolarization (DAD) or both, is unknown. Methods and Results—: We investigated isolated cardiomyocytes from a murine model with heterozygous knockout of NCX (hetKO) using the patch clamp and Ca 2+ imaging techniques. Action potential duration was shorter in hetKO with I Ktot not being increased. The rate of spontaneous Ca 2+ release events and the rate of DADs were unaltered; however, DADs had lower amplitude in hetKO. A DAD triggered a spontaneous action potential significantly less often in hetKO when compared with wild-type. The occurrence of EADs was also drastically reduced in hetKO. I Ca activity was reduced in hetKO, an effect that was abolished in the presence of the Ca 2+ buffer BAPTA. Conclusions—: Genetic suppression of NCX reduces both EADs and DADs. The following molecular mechanisms apply: (1) Although the absolute number of DADs is unaffected, an impaired translation of DADs into spontaneous action potentials results from a reduced DAD amplitude. (2) EADs are reduced in absolute number of occurrence, which is presumably a consequence of shortened action potential duration because of reduced NCX activity but also reduced I Ca the latter possibly being caused by a direct modulation of Ca 2+ -dependent I Ca inhibition by reduced NCX activity. This is the first study to demonstrate that genetic inhibition of NCX protects against afterdepolarizations and to investigate the underlying mechanisms.
1 June 2013 in International Journal of Cardiology
Dephosphorylation of important myocardial proteins is regulated by protein phosphatase 2A (PP2A), representing a heterotrimer that is comprised of catalytic, scaffolding, and regulatory (B) subunits. There is a multitude of B subunit family members directing the PP2A holoenzyme to different myocellular compartments. To gain a better understanding of how these B subunits contribute to the regulation of cardiac performance, we generated transgenic (TG) mice with cardiomyocyte-directed overexpression of B56α, a phosphoprotein of the PP2A-B56 family. The 2-fold overexpression of B56α was associated with an enhanced PP2A activity that was localized mainly in the cytoplasm and myofilament fraction. Contractility was enhanced both at the whole heart level and in isolated cardiomyocytes of TG compared with WT mice. However, peak amplitude of [Ca]i did not differ between TG and WT cardiomyocytes. The basal phosphorylation of cardiac troponin inhibitor (cTnI) and the myosin-binding protein C was reduced by 26 and 35%, respectively, in TG compared with WT hearts. The stimulation of β-adrenergic receptors by isoproterenol (ISO) resulted in an impaired contractile response of TG hearts. At a depolarizing potential of -5 mV, the ICa,L current density was decreased by 28% after administration of ISO in TG cardiomyocytes. In addition, the ISO-stimulated phosphorylation of phospholamban at Ser(16) was reduced by 27% in TG hearts. Thus, the increased PP2A-B56α activity in TG hearts is localized to specific subcellular sites leading to the dephosphorylation of important contractile proteins. This may result in higher myofilament Ca(2+) sensitivity and increased basal contractility in TG hearts. These effects were reversed by β-adrenergic stimulation.
1 November 2017 in Progress in Biophysics and Molecular Biology